BIOSYNGEN PTE. LTD.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting 2024-09-20 20:30
Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024 2024-09-19 20:30
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress 2024-09-18 18:18
Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial 2024-08-13 09:00
Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy 2024-08-01 16:01
Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma 2024-07-16 19:29
Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma 2024-07-16 17:10
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer 2024-02-01 17:41
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA 2023-10-26 18:18
Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023 2023-09-18 17:53
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors 2023-09-11 14:53
Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation 2023-07-12 13:38
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone. 2023-07-12 10:32
Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore 2023-06-29 17:14
Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer 2023-06-06 12:58
Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma 2023-04-18 19:03
Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma 2023-04-11 18:09
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy 2023-03-29 22:53
Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer 2023-02-17 23:13
IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA 2022-12-15 13:08
1 2